Dimitrios Mougiakakos


Professur für Hämatologie/Onkologie mit dem Schwerpunkt Tumorimmunologie

Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 4 Go to next page Go to last page

Bruns, H., Jitschin, S., Gamali, S., Saul, D., Böttcher, M., Mackensen, A.,... Mougiakakos, D. (2019). A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction. Leukemia. https://dx.doi.org/10.1038/s41375-018-0345-0
Haug, T., Aigner, M., Peuser, M.M., Strobl, C., Hildner, K., Mougiakakos, D.,... Völkl, S. (2019). Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity. Frontiers in Immunology, 10. https://dx.doi.org/10.3389/fimmu.2019.00883
Jitschin, R., Böttcher, M., Saul, D., Lukassen, S., Bruns, H., Loschinski, R.,... Mougiakakos, D. (2019). Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation. Leukemia. https://dx.doi.org/10.1038/s41375-018-0376-6
Jitschin, R., Saul, D., Braun, M., Tohumeken, S., Völkl, S., Kischel, R.,... Mougiakakos, D. (2018). CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. Journal for ImmunoTherapy of Cancer, 6(1). https://dx.doi.org/10.1186/s40425-018-0432-9
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z.E.,... Mougiakakos, D. (2018). D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. OncoImmunology, 7(7). https://dx.doi.org/10.1080/2162402X.2018.1445454
Loschinski, R., Böttcher, M., Stoll, A., Bruns, H., Mackensen, A., & Mougiakakos, D. (2018). IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. Oncotarget, 9(17), 13125-13138. https://dx.doi.org/10.18632/oncotarget.24442
Busch, L., Mougiakakos, D., Büttner-Herold, M., Müller, M.J., Volmer, D.A., Bach, C.,... Bruns, H. (2018). Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia. https://dx.doi.org/10.1038/s41375-018-0114-0
Iacobaeus, E., Douagi, I., Jitschin, R., Marcusson-Stahl, M., Andren, A.T., Andren, A.T.,... Le Blanc, K. (2018). Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis. Immunology and Cell Biology, 96(8), 820-830. https://dx.doi.org/10.1111/imcb.12042
Schwab, A., Siddiqui, A., Vazakidou, M.E., Napoli, F., Böttcher, M., Menchicchi, B.,... Ceppi, P. (2018). Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. Cancer Research. https://dx.doi.org/10.1158/0008-5472.CAN-17-2834
Chaturvedi, A., Cruz, M.M.A., Goparaju, R., Gabdoulline, R., Schottmann, R., Goerlich, K.,... Heuser, M. (2018). Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.

Zuletzt aktualisiert 2018-17-09 um 23:51